Before you continue… You really need to read this if you have diabetes. CLICK HERE now.(will open in new window)
Find The Lowest Price Right Here
Sharklet Technologies, Incorporated. Reported nowadays that it's been awarded a $1.2 million Small Business Invention analysis (SBIR) segment II grant by the Nation's Institutes of well being (NIH) / national Institute of Diabetes and Digestive and Kidney Diseases* to resume its construction of a urinary Foley catheter with the Sharklet(TM) micro-pattern that inhibits bacterial expansion on the floor of the catheter. As a section of the study project, the corporate expects to conduct a tiny human clinical trial to guage in vivo efficacy. Simultaneous to its research, the company will submit a 510K application to the FDA. Sharklet Technologies’ Director of Research Dr. Shravanthi Reddy, who led Phase I research, will serve as the principal investigator for the Phase II project.
“We are pleased to receive this significant award as it validates our use of a novel topography-based, non-chemical way to inhibit bacterial biofilm development,” mentioned Dr. Reddy. “Thru our continued development of a Sharklet-patterned Foley catheter our objective stays unchanging – to strengthen catheter generation by decreasing catheter-assosicated urine tract infections, or CAUTI, which may toughen affected person outcomes and improve health care financials.” . CAUTIs account for roughly forty % of the two million annually happening hospital-acquired diseases.
approximately 95 percent of urinary tract contagions are associated with urinary catheters. these contagions account for an approximate $565 million yearly in further costs to sufferers and the health care system. About 8 thousand patients die each 12 months from CAUTI.
Additionally, in 2008, Medicare commented that it will no longer pay for treatment of preventable hospital-acquired contagions due to urinary catheters effectively making hospitals economically responsible for reducing the frequency of these infections. Today’s urinary catheter technology suffers from key flaws, most notably that they often cause an infection due to micro organism colonising the outer layer of the catheter. Current antimicrobial catheters depend on biocides to cover the catheter before insertion or anti-microbe dealers manufactured directly into the surface of the catheter. These chemically-coated catheters elute their anti-microbial agents into pee, which can end up in the emergence and choice of antimicrobial-resistant strains of micro organism. The Sharklet micro-pattern is unique in it is a surface texture – not chemical elution – that inhibits bacterial colonization. This non-toxic approach reduces the risk of development of multi-drug resistant micro organism species.
”Sharklet represents an innovation in bacterial control and the culmination of years of work in deciding how surface topography can impact microorganism growth,” said Mark Spiecker prnewswire, chief executive officer of Sharklet applied sciences. “We are thankful for this award as it underscores the significance of introducing new non-kill applied sciences to advance our standards for healthcare particularly as it applies to infection prevention.” . Sharklet Technologies, Inc. Impressed by the microbial-resistant properties of sharkskin, Sharklet(TM), the company’s middle technology, is the planet's first micro-pattern developed to regulate bacteria including Staph, MRSA, VRE, E. Coli and a bunch of others. Sharklet(TM) is suited for commercial, healthcare, food service and laboratory environments where bacterial inhibition is desired to assist in protecting human health.
The content is solely the responsibility of the authors and doesn't always constitute the official perspectives of the National Institute of Diabetes and Digestive and Kidney Sicknesses or the National Institutes of Health.